BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1280 related articles for article (PubMed ID: 20887192)

  • 1. EGFR mutations and lung cancer.
    da Cunha Santos G; Shepherd FA; Tsao MS
    Annu Rev Pathol; 2011; 6():49-69. PubMed ID: 20887192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.
    Roengvoraphoj M; Tsongalis GJ; Dragnev KH; Rigas JR
    Cancer Treat Rev; 2013 Dec; 39(8):839-50. PubMed ID: 23768755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Jänne PA; Johnson BE
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
    Gadgeel SM; Wozniak A
    Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer.
    Tomizawa Y; Iijima H; Sunaga N; Sato K; Takise A; Otani Y; Tanaka S; Suga T; Saito R; Ishizuka T; Dobashi K; Minna JD; Nakajima T; Mori M
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6816-22. PubMed ID: 16203769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer: impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors.
    Cohen V; Agulnik JS; Ang C; Kasymjanova G; Batist G; Small D; Brandao G; Chong G; Miller WH
    Cancer; 2010 Sep; 116(18):4309-17. PubMed ID: 20549828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of EGFR mutation analysis in non-small cell lung cancer.
    Yamamoto H; Toyooka S; Mitsudomi T
    Lung Cancer; 2009 Mar; 63(3):315-21. PubMed ID: 18760859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erlotinib in the first-line treatment of non-small-cell lung cancer.
    D'Arcangelo M; Cappuzzo F
    Expert Rev Anticancer Ther; 2013 May; 13(5):523-33. PubMed ID: 23617344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification.
    Okabe T; Okamoto I; Tamura K; Terashima M; Yoshida T; Satoh T; Takada M; Fukuoka M; Nakagawa K
    Cancer Res; 2007 Mar; 67(5):2046-53. PubMed ID: 17332333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop.
    Pirker R; Herth FJ; Kerr KM; Filipits M; Taron M; Gandara D; Hirsch FR; Grunenwald D; Popper H; Smit E; Dietel M; Marchetti A; Manegold C; Schirmacher P; Thomas M; Rosell R; Cappuzzo F; Stahel R;
    J Thorac Oncol; 2010 Oct; 5(10):1706-13. PubMed ID: 20871269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway.
    Rosell R; Taron M; Reguart N; Isla D; Moran T
    Clin Cancer Res; 2006 Dec; 12(24):7222-31. PubMed ID: 17189393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.
    Bonomi PD; Buckingham L; Coon J
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4606-12. PubMed ID: 17671150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.
    Ohtsuka K; Ohnishi H; Fujiwara M; Kishino T; Matsushima S; Furuyashiki G; Takei H; Koshiishi Y; Goya T; Watanabe T
    Cancer; 2007 Feb; 109(4):741-50. PubMed ID: 17238183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.
    Kawahara A; Azuma K; Sumi A; Taira T; Nakashima K; Aikawa E; Abe H; Yamaguchi T; Takamori S; Akiba J; Kage M
    Lung Cancer; 2011 Oct; 74(1):35-40. PubMed ID: 21444121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A diagnostic algorithm using EGFR mutation-specific antibodies for rapid response EGFR-TKI treatment in patients with non-small cell lung cancer.
    Kawahara A; Taira T; Azuma K; Tominaga M; Hattori S; Kawahara M; Abe H; Yamaguchi T; Akiba J; Takamori S; Hayashi A; Kage M
    Lung Cancer; 2012 Oct; 78(1):39-44. PubMed ID: 22858448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.
    Park SJ; Kim HT; Lee DH; Kim KP; Kim SW; Suh C; Lee JS
    Lung Cancer; 2012 Sep; 77(3):556-60. PubMed ID: 22677429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients.
    Chang JW; Liu HP; Hsieh MH; Fang YF; Hsieh MS; Hsieh JJ; Chiu YT; Tsai HY; Chen YH; Chen YT; Hsu HY; Chen YT; Tsai SF; Chen YR; Hsi BL; Huang SF
    Lung Cancer; 2008 Sep; 61(3):328-39. PubMed ID: 18304690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors predicting response to EGFR tyrosine kinase inhibitors.
    Engelman JA; Jänne PA
    Semin Respir Crit Care Med; 2005 Jun; 26(3):314-22. PubMed ID: 16052433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR inhibitors as first-line therapy in EGFR mutation-positive patients with NSCLC.
    Gorden KJ; Mesbah P; Kolesar JM
    J Oncol Pharm Pract; 2012 Jun; 18(2):245-9. PubMed ID: 21733906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting epidermal growth factor receptor: central signaling kinase in lung cancer.
    Yoshida T; Zhang G; Haura EB
    Biochem Pharmacol; 2010 Sep; 80(5):613-23. PubMed ID: 20519133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 64.